Blog

Francisco Esteva: Learn about PI3K Pathway Inhibitors in HR+ Metastatic Breast Cancer

Francisco Esteva/LinkedIn

May 28, 2025, 11:58

Francisco Esteva: Learn about PI3K Pathway Inhibitors in HR+ Metastatic Breast Cancer

Francisco Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital and a Professor of Medicine at the Zucker School of Medicine, shared a post on LinkedIn:

“Drugs that target the PI3 Kinase pathway in breast cancer, including Alpelisib, Inavolisib, and Capivasertib offer new hope for patients with PIK3CA mutations.

In this video, I explain how PI3K and AKT inhibitors work, their role in managing hormone receptor-positive metastatic breast cancer, and the importance of biomarker testing. Learn how these drugs are transforming treatment strategies and what to expect in terms of efficacy and side effects.

This information will serve as background to understand the impact of these and other drugs (e.g., ipatasertib) that will be presented at ASCO25.”

Francisco Esteva discussed the therapeutic role of PI3K and AKT inhibitors in managing hormone receptor-positive metastatic breast cancer. His overview includes drug mechanisms, biomarker relevance, and expected data updates at ASCO 2025.

More posts featuring Francisco Esteva.

alpelisib ASCO25 cancer Capivasertib fight against cancer Francisco Esteva Global fight against cancer HR+ Inavolisib ipatasertib Lenox Hill Hospital metastatic breast cancer OncoDaily Oncology PI3K Pathway Inhibitors PIK3CA mutations Zucker School of Medicine

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action